Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used to improve glycaemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Combination therapy: can be added to metformin, sulfonylureas or insulin to achieve target HbA1c. - Renal impairment: provides glycaemic control without dose adjustment in patients with reduced kidney function.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient mild to moderate headache. - Gastrointestinal upset: includes nausea or abdominal discomfort. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as angioedema, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatic injury: abnormal liver enzymes or jaundice. - Bullous pemphigoid: rare skin blistering disorder.

Linagliptin should be used with clinical monitoring and awareness of potential risks. - Renal function: assess baseline renal status and monitor periodically. - Hepatic function: evaluate liver enzymes before initiation and during therapy. - Pancreatitis: discontinue if signs of acute pancreatitis appear. - Allergic reactions: watch for rash, swelling, or breathing difficulties. - Hypoglycaemia risk: higher when combined with insulin or sulfonylureas. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring careful management. Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin exposure. - Strong P‑gp inhibitors (e.g., itraconazole): may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Rifampin: enzyme induction may reduce linagliptin effectiveness. - Diuretics: may affect glucose control and renal handling. - NSAIDs: concurrent use may impact renal function, especially in susceptible patients.